Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Risankizumab for the treatment of moderate-to-severe psoriasis: A multicenter, retrospective, 1 year real-life study.
Caldarola G, Zangrilli A, Bernardini N, Bavetta M, De Simone C, Graceffa D, Bonifati C, Faleri S, Giordano D, Mariani M, Micheli A, Moretta G, Pagnanelli G, Panasiti V, Provini A, Richetta A, Peris K, Bianchi L. Caldarola G, et al. Among authors: bavetta m. Dermatol Ther. 2022 Jun;35(6):e15489. doi: 10.1111/dth.15489. Epub 2022 Apr 13. Dermatol Ther. 2022. PMID: 35385202 Free PMC article.
Risankizumab: How to choose the right dose in clinical practice?
Pensa C, Piccolo A, Zangrilli A, Bavetta M, Bianchi L. Pensa C, et al. Among authors: bavetta m. Dermatol Ther. 2020 Nov;33(6):e14371. doi: 10.1111/dth.14371. Epub 2020 Oct 20. Dermatol Ther. 2020. PMID: 33021745 No abstract available.
A single-centre, observational, retrospective, real-life study evaluating adalimumab biosimilar ABP 501 in the treatment of plaque-type psoriasis and psoriatic arthritis in originator-naïve patients and in patients undergoing non-medical switch from originator.
Giunta A, Zangrilli A, Bavetta M, Manfreda V, Pensa C, Bianchi L. Giunta A, et al. Among authors: bavetta m. Curr Med Res Opin. 2021 Jul;37(7):1099-1102. doi: 10.1080/03007995.2021.1923467. Epub 2021 May 20. Curr Med Res Opin. 2021. PMID: 34011212
Predictive factors of lack of response to adalimumab among bio-naive patients suffering from moderate-to severe psoriasis: analysis of a multicenter data collection in Italy.
Zangrilli A, Caldarola G, Bernardini N, Bavetta M, Graceffa D, Bonifati C, Cantoresi F, Faleri S, Giordano D, Mariani M, Micheli A, Moretta G, Pirro F, Pagnanelli G, Panasiti V, Provini A, Richetta A, Sacchelli L, Bianchi L, Peris K. Zangrilli A, et al. Among authors: bavetta m. Expert Opin Biol Ther. 2021 Sep;21(9):1291-1298. doi: 10.1080/14712598.2021.1948530. Epub 2021 Jul 18. Expert Opin Biol Ther. 2021. PMID: 34278889
Is weekly dose of adalimumab a simple approach for resistant psoriasis?
Mazzilli S, Zangrilli A, Bavetta M, Bianchi L. Mazzilli S, et al. Among authors: bavetta m. J Dermatolog Treat. 2018 May;29(3):233-234. doi: 10.1080/09546634.2017.1364689. Epub 2017 Aug 18. J Dermatolog Treat. 2018. PMID: 28777015 No abstract available.
43 results